Loading...
•
Jun 30, 2020
STERIS Q1 2021 Earnings Report
STERIS's first quarter results reflected a balanced business model and were impacted by reduction in deferrable procedures, with revenue declining and net income growing.
Key Takeaways
STERIS plc reported a 4% decrease in revenue to $668.9 million, driven by declines in Healthcare and Applied Sterilization Technologies, offset by growth in Life Sciences. Net income increased to $88.2 million, or $1.03 per diluted share, compared to $84.6 million, or $0.99 per diluted share in the previous year.
First quarter revenue declined low-single digits due to reduction in deferrable procedures.
First quarter net income grew low-single digits driven by margin expansion.
Healthcare segment was most impacted by the reduction of deferrable procedures, with revenue declining 10%.
Life Sciences segment continued its strong performance, with revenue growing 21%.
Revenue by Segment
Forward Guidance
Due to the continuing uncertainty, STERIS is not providing guidance for fiscal year 2021.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...